Hao Shuai, Huang Miao, Tian Wuguo, Chen Yi, Zhao Jianjie, Luo Donglin
Department of Breast, Thyroid Surgery, Daping Hospital, Army Medical University, Chongqing, China.
Nursing School, Chongqing Medical University, Chongqing, China.
J Breast Cancer. 2020 Dec;23(6):656-664. doi: 10.4048/jbc.2020.23.e63.
Male breast cancer (MBC) is rare and accounts for approximately 1% of all breast cancer cases worldwide. Previous studies have suggested that several factors significantly increase the risk of MBC. Prolactinoma has the highest incidence rate among patients with functional pituitary tumors. However, whether prolactinoma is involved in the onset and progression of breast cancer remains unclear. To date, there are only five case reports globally on MBC with concurrent prolactinoma. We hereby describe the first case of MBC with prolactinoma in China. We also explored the patient's genetic profile using whole exome sequencing. Our findings may help advance our understanding of the molecular pathogenesis of MBC. Further molecular analyses of such cases are warranted to improve auxiliary molecular diagnostic methods and targeted therapy for MBC.
男性乳腺癌（MBC）较为罕见，约占全球所有乳腺癌病例的1%。既往研究表明，有几个因素会显著增加MBC的发病风险。泌乳素瘤在功能性垂体肿瘤患者中发病率最高。然而，泌乳素瘤是否参与乳腺癌的发生和发展仍不清楚。迄今为止，全球仅有5例关于合并泌乳素瘤的MBC病例报告。我们在此描述中国首例合并泌乳素瘤的MBC病例。我们还使用全外显子测序技术探究了该患者的基因图谱。我们的研究结果可能有助于增进我们对MBC分子发病机制的理解。有必要对这类病例进行进一步的分子分析，以改进MBC的辅助分子诊断方法和靶向治疗。
